Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
80 participants
OBSERVATIONAL
2022-11-01
2025-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tracer Targeting FAP PET Imaging in Patients
NCT05691894
The Role of 18F-FDG-PET/CT Scan in Lung Cancer Patients
NCT04395651
18F-FAPI PET/CT in Patients With Various Types of Cancer
NCT05810324
Brown Adipose Tissue Activity and Energy Metabolism in Cachexia
NCT02500004
Imaging 61CuATSM Uptake in Atherosclerotic Plaque Using PET-CT
NCT01000181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PET/CT
18F-fluorodeoxyglucose positron emission tomography/computed tomography (18FFDG PET/CT) is a non-invasive imaging modality used for staging and surveillance of various types of malignancies through imaging of glucose metabolism in cancer cells.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients conscious to provide informed consent
Exclusion Criteria
* Intolerance of PET/CT due to claustrophobia will be excluded from the study.
* Patients under age of 18
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mona Nabil Helbawi
resident doctor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BAT activation in PET/CT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.